infectious disease and antimicrobial resistance (AMR)
With emerging disease at the forefront of global health priorities as never before, The Bloomsbury SET is developing new solutions to combat infectious disease and antimicrobial resistance (AMR).
Through our new Impact Connector programme, we are enabling the best technologies to move closer to market by working with business to accelerate the development of new tools for the prevention and treatment of infectious diseases of humans and animals.
At the same time, we are developing the skills of our academics and professional staff to enhance institutional capacity for supporting commercialisation, leading to the creation of new knowledge ecosystems that link universities to industry partners and investors.
From July 2021, The Bloombury SET partners include The Royal Veterinary College (RVC), The London School of Hygiene & Tropical Medicine (LSHTM), SOAS University of London (SOAS), and the Infection Innovation Consortium (iiCON), led by the Liverpool School of Tropical Medicine (LSTM). We will also continue working closely with the London International Development Centre (LIDC), and industry partners.
Starting in April 2018, the first phase of this translational research programme has focused on the development of new vaccines, diagnostic tools and addressing innovative approaches for data analysis and public health. Its original partnership included the Royal Veterinary College (RVC), the London School of Hygiene & Tropical Medicine (LSHTM), and SOAS University of London (SOAS), the London School of Economics and Political Science (LSE) and the London International Development Centre (LIDC).
Building on the current work of The Bloomsbury SET, a new programme, entitled ‘The Bloomsbury SET: A London-Liverpool alliance to accelerate solutions to infectious diseases and antimicrobial resistance’ started in July 2021 and retains three of the four original collaborating institutions. Joining the RVC, LSHTM and SOAS, is a new partner, the Infection Innovation Consortium (iiCON), led by the Liverpool School of Tropical Medicine (LSTM). We also work closely in conjunction with the London International Development Centre (LIDC) that is shaping the future of international development.
The Impact Connector programme aims to improve our partners’ capacity for the support and delivery of translational research along the commercialisation route.
The new programme targets academics and university staff across the consortium to improve their knowledge and understanding of commercialisation, as well as creating new opportunities for partnerships with companies in support of product development. These activities aim to develop a pipeline of skilled innovators and support staff, to boost competition of ideas and to progress to higher Technology Readiness Levels.
The programme brings complementary expertise, resources and infrastructure from renowned institutions to address the challenges of infectious diseases.
We encourage collaboration amongst our research academics and industry partners by creating an innovation ecosystem that supports the development of tools such as vaccines, diagnostics and therapeutics to provide major human health benefits, as well as improvements in animal health, welfare and productivity, biosecurity and food safety.